Medicare AdvantageCoverageMedium impact
MA06.006g, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy
Independence Blue Cross·Infectious Disease, Family Medicine, Internal Medicine +1 more·Medical Policy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.006g for Lyme Disease diagnosis and IV antibiotic therapy has been updated with changes to coverage position and medical necessity criteria. This affects reimbursement and coverage determinations for Lyme disease treatment with intravenous antibiotics.
Action Required
By December 29, 2025: Billing team must review the full policy MA06.006g at medpolicy.ibx.com to understand new medical necessity criteria for Lyme disease IV antibiotic therapy. Update prior authorization processes and documentation requirements for IV antibiotic treatments. Ensure providers document medical necessity according to updated criteria to avoid claim denials.